In vitro development of resistance to five quinolones and amoxicillin- clavulanate in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1177-1182

  Davies, Todd A ^a   Pankuch, Glenn A ^a   Dewasse, Bonifacio E ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GREPAFLOXACIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CROSS REACTION; DNA SEQUENCE; GENE ISOLATION; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 0032930271     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1177     Document Type: Article

References (23)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Appelbaum, P. C., S. K. Spangler, E. Crotty, and M. R. Jacobs. 1989. Susceptibility of penicillin-sensitive and penicillin-resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime, and quinolones. J. Antimicrob. Chem. 23:509-516.
3. Baranova, N. N., and A. A. Neyfakh. 1997. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother, 41:1396-1398.
4. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
5. Campbell, G. D., Jr., and R. Silberman. 1998. Drug-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 26:1188-1195.
6. Felmingham, D. 1998. Personal communication.
7. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
8. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
9. Jacobs, M. R., S. Bajaksouzian, G. Lin, and P. C. Appelbaum. 1998. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral agents: results of 1997 epidemiological survey, abstr. A-31, p. 43. In Abstracts of the 98th General Meeting of the American Society for Microbiology 1998. American Society for Microbiology, Washington, D.C.
10. Janoir, C., V. Zeller, M. Kitzis, N. J. Moreau, and L. Gutmann. 1996. Highlevel fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
11. Moissenet, D., M. Valcin, V. Marchand, E.-N. Garabédian, P. Geslin, A. Garbarg-Chenon, and H. Vu-Thien. 1997. Molecular epidemiology of Streptococcus pneumoniae with decreased susceptibility to penicillin in a Paris children's hospital. J. Clin. Microbiol. 35:298-301.
12. Muñoz, R., and A. G. De la Campa. 1996. ParC subunit of DNA topoisoraerase IV of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40: 2252-2257.
13. National Committee for Clinical Laboratory Standards. 1998. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing. M100-S8. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
16. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996, Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
17. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
18. Pankuch, G. A., S. A. Jueneman, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 1998. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2914-2918.
19. Perichon, B., J. Tankoric, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
20. Piddock, L. J. V. 1994, New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
21. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
22. Thys, J. P., F. Jacobs, and B. Byl. 1991. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10:304-315.
23. Yoshida, H., M. Bogaki, S. Nakmnura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.